Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The t

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July’s sharp pullback.

Indivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +18.56% and +11.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) said Monday that they will merge

Opioid addiction has cast a shadow over the U.S. But this pharma stock, which targets the issue, is eyeing a fresh entry as profits soar.

Howard Marks just filed five equity positions that look nothing like a bull-market portfolio, and every one has moved sharply since he bought. The question now is whether his thesis still holds at today's prices.

On 27 June 2026, Indivior Pharmaceuticals, Inc. (NasdaqGS: INDV) was added to the Russell 2000 Defensive, Russell 2000 Growth‑Defensive and Russell 2000 Value‑Defensive Indexes, broadening its presence across multiple index benchmarks. This triple index inclusion, alongside recently highlighted earnings estimate revisions and fundamental momentum, may increase Indivior’s visibility with institutional investors and index‑tracking funds. We’ll now examine how Indivior’s addition to multiple...

Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.